• Chest · Mar 2014

    Epidemiological and survival analysis of bronchopulmonary carcinoids, 2000 - 2010.

    • Srinadh Annangi, Hari Prasad Ravipati, Swathi Nutakki, Eric Flenaugh, and Christine Charaf.
    • Chest. 2014 Mar 1;145(3 Suppl):336A.

    Session TitleLung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchopulmonary (BP) carcinoids are rare neuroendocrine tumors comprising of 1.1 % of all pulmonary cancers. To our knowledge no single study had been done using large cancer database evaluating bronchopulmonary carcinoids in particular with respect to their anatomical distribution and the impact of staging, histological grade, treatment offered and racial distribution on five year relative survival rates.MethodsWe analyzed the Surveillance, Epidemiology, and End Results (SEER) database from 18 registries for anatomical, demographic and histological distribution of bronchopulmonary carcinoids and their survival impact.ResultsOf the 6225 bronchopulmonary carcinoids, 4235(68%) were diagnosed in females and 1990(32%) in males. 90% cases were whites, 6.9% blacks, 2.3% Asian/Pacific islanders and 0.3% Native American/Alaskan. 5yr relative survival rates were 80.2% in blacks and 90.2% in whites. BP carcinoids account for 20.09% of all carcinoids of which 8.11% were lower lobe (LL), 5.85% upper lobe(UL) and 3.55% middle lobe(ML) tumors. 5yr relative survivals for bronchial, upper lobe, middle and lower lobe carcinoids are 89.0%, 88.9%, 96.0% and 91.2% respectively. Atypical carcinoids comprise of 7% of bronchopulmonary carcinoids with 5yr relative survival rate of 62.8%. 66.1% had localized, 17.6% regional and 11.7% distant spread BP carcinoids and their relative survival rates were 97.9%, 84.2% and 54.1% respectively. 69.9%, 17.6%, 9.4% of UL carcinoids, 74%, 16.3%, 6.6% of ML and 68.4%, 17.8%, 9.4% of LL carcinoids are staged as having localized, regional and distant spread respectively. Survival rates in non-surgical cases were 56.8% compared to 96.8% for surgical cases.ConclusionsThere has been over all increase in the incidence of bronchopulmonary carcinoids, more common in females with female to male ratio of 2.1:1. Incidence rates were highest in the seventh decade of life. Low survival rates in blacks could be attributed to lower surgery rates in blacks (71.2%) compared to whites (83%). Staging is a strong predictor of survival. Upper lobe carcinoid in males with distant spread had the least survival rate. Surgery definitely increases 5yr relative survival rates.Clinical ImplicationsStaging is the strongest predictor of survival. Upper lobe carcinoids in males has least survival. Surgery remains the main stay of treatment for BP carcinoids.DisclosureThe following authors have nothing to disclose: Hari Prasad Ravipati, Srinadh Annangi, Swathi Nutakki, Christine Charaf, Eric FlenaughNo Product/Research Disclosure Information.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,624,503 articles already indexed!

We guarantee your privacy. Your email address will not be shared.